NEW YORK, NY / ACCESSWIRE / October 26, 2018 / U.S. equities bounced back on Thursday supported mostly by gains in consumer discretionary and technology shares. The Dow Jones Industrial Average jumped 1.63 percent to close at 24,984.55, as Microsoft topped analysts' earnings expectations, while the S&P 500 Index increased 1.86 percent to close at 2,705.57. The Nasdaq Composite Index surged 2.95 percent to close at 7,318.34, lifted by gains in Facebook and Netflix.
According to the co-chief investment strategist at The PNC Financial Services Group, Amanda Agati
"What is surprising to me is where the finger is being pointed at. It's not clear to me that anything has changed in the last month”, she added.
RDI Initiates Coverage on:
Gilead Sciences, Inc.
Esperion Therapeutics, Inc.
Gilead Sciences, Inc.'s stock moved 0.9% higher Thursday, to close the day at $68.62. The stock recorded a trading volume of 9,225,463 shares, which was above its three months average volume of 6,391,806 shares. In the last year, Gilead Sciences, Inc.'s shares have traded in a range of 64.27 - 89.54. The share price has gained 6.77% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $74.53 is above its 200-day moving average of $73.24. Shares of the company are trading at a Price to Earnings ratio of 40.99. Shares of Gilead Sciences, Inc. have fallen roughly 8.49 percent in the past month and are down 2 percent year-to-date.
Access RDI's Gilead Sciences, Inc. Research Report at:
On Thursday, shares of Esperion Therapeutics, Inc. recorded a trading volume of 1,403,066 shares, which was above the three months average volume of 554,510 shares. The stock ended the day 9.36% lower at $36.99. The share price has fallen 55.26% from its 52
Access RDI's Esperion Therapeutics, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.